ASCOT a Four Horse Race

Dahlöf B. , Sever PS , Poulter NR et al; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.

Poulter NR , Wedel H. , Dahlöf B. et al; for the ASCOT Investigators Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-13

Furberg CD , Psaty BM Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective. Cardiovasc Drugs Ther 1996; 10:463-6.

Sever PS , Dahlöf B. , Poulter NR et al; for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.

Williams B. , Poulter NR , Brown MJ et al; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.

Hypertension Detection and Follow-up Programme Cooperative Group (HDFP). Five-year findings of the Hypertension Detection and Follow-up Programme: reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-571.

Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.

Williams B. The renin angiotensin system and cardiovascular disease: hope or hype? JRAAS 2000;2:142-6.

Staessen JA , Thijs L. , Birkenhager WH Evidence that new antihypertensives are superior to older drugs. Lancet 2005; 366:869-70.

Staessen JA , Li Y. , Thijs L. , Wang JG Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials . Hypertens Res 2005;28:385-407.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 2002;23:2981-97.

Julius S. , Kjeldsen SE , Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.